• Bicara Therapeutics CEO Claire Mazumdar exercised stock options for 10,000 shares at $3.79 on July 10, 2026.
• She sold 10,000 shares the same day at an average $28.42, cutting her direct stake to 362,152 shares.
• Her remaining stock options totaled 120,546 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000714), on July 14, 2026, and is solely responsible for the information contained therein.